David Badawi Sells 8,168 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 8,168 shares of Sight Sciences stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $3.48, for a total value of $28,424.64. Following the completion of the sale, the chief technology officer owned 1,990,290 shares of the company’s stock, valued at approximately $6,926,209.20. The trade was a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Badawi also recently made the following trade(s):

• On Friday, January 16th, David Badawi sold 4,836 shares of Sight Sciences stock. The stock was sold at an average price of $6.62, for a total value of $32,014.32.
• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $27,638.60.
• On Monday, January 5th, David Badawi sold 3,051 shares of Sight Sciences stock. The shares were sold at an average price of $7.82, for a total transaction of $23,858.82.

Sight Sciences Price Performance

Shares of NASDAQ:SGHT opened at $3.52 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 10.22 and a quick ratio of 9.52. The stock has a market cap of $190.12 million, a price-to-earnings ratio of -4.69 and a beta of 2.50. The company has a 50 day moving average of $4.82 and a 200-day moving average of $5.74. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $9.24.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.07. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. The firm had revenue of $20.39 million for the quarter, compared to analysts’ expectations of $20.35 million. On average, sell-side analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Sight Sciences

A number of large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Sight Sciences during the fourth quarter worth $109,000. Invesco Ltd. acquired a new stake in shares of Sight Sciences during the 4th quarter worth about $2,791,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Sight Sciences during the 4th quarter worth about $185,000. Millennium Management LLC boosted its holdings in shares of Sight Sciences by 99.4% during the 4th quarter. Millennium Management LLC now owns 266,919 shares of the company’s stock worth $2,117,000 after buying an additional 133,073 shares during the period. Finally, Bridgeway Capital Management LLC grew its stake in Sight Sciences by 4.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 100,733 shares of the company’s stock valued at $799,000 after buying an additional 4,300 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on SGHT. Citigroup decreased their price objective on Sight Sciences from $9.10 to $6.50 and set a “neutral” rating for the company in a research note on Friday, March 6th. Stifel Nicolaus upped their target price on Sight Sciences from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Raymond James Financial set a $9.00 price target on Sight Sciences in a research report on Monday, January 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a report on Monday, December 29th. Finally, Piper Sandler set a $9.00 price target on shares of Sight Sciences in a research report on Monday, January 5th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.31.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.